Allylescaline Stats & Data
NCCc1cc(OC)c(OCC=C)c(OC)c1JNUAYHHGCXYBHX-UHFFFAOYSA-NPharmacology
DrugBankDescription
A metallic element that has the atomic number 13, atomic symbol Al, and atomic weight 26.98.
Mechanism of Action
Aluminum Acetate is an astringent. An astrignent is a chemical that tends to shrink or constrict body tissues, usually locally after topical medicinal application. The shrinkage or constriction is through osmotic flow of water (or other fluids) away from the area where the astringent was applied. Astringent medicines cause shrinkage of mucous membranes or exposed tissues and are often used internally to check discharge of blood serum or mucous secretions. This can happen with a sore throat, hemorrhages, diarrhea, or with peptic ulcers. Externally applied astringents, which cause mild coagulation of skin proteins, dry, harden, and protect the skin. Acne sufferers are often advised to use astringents if they have oily skin. Astringents also help heal stretch marks and other scars. Mild astringent solutions are used in the relief of such minor skin irritations as those resulting from superficial cuts, allergies, insect bites, or fungal infections such as athlete's foot.
Receptor Profile
Receptor Actions
History & Culture
Allylescaline was first documented in the scientific literature by Czech chemist Otakar Leminger in 1972. The compound received broader attention when American chemist Alexander Shulgin synthesized and characterized its psychoactive effects, publishing his findings in the 1991 book PiHKAL: A Chemical Love Story. In PiHKAL, Shulgin described allylescaline's subjective effects and established dosage parameters based on his bioassay methodology. The compound remained relatively obscure for over two decades following PiHKAL's publication. It emerged on the research chemical market in 2013, when it was identified as a novel designer drug being sold online. This appearance prompted regulatory responses in several countries during the mid-2010s.
Effect Profile
Curated + 20 ReportsStrong visuals, headspace, auditory effects, and body load
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Experience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 20 experience reports (20 Erowid)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 9
Adverse Effects 7
Dosage Distribution
Dose distribution from experience reports
Real-World Dose Distribution
62K DosesFrom 33 individual dose entries
Oral (n=30)
Form / Preparation
Most common forms and preparations reported
Body-Weight Dosing
Dose relative to body weight from reports with weight data
Redose Patterns
Redosing behavior across 15 reports
Legal Status
| Country | Status | Notes |
|---|---|---|
| Germany | Anlage I BtMG | Controlled under the Narcotics Act (Betäubungsmittelgesetz) Schedule I since February 1, 1997, listed as '4-Allyloxy-3,5-dimethoxy-phenethylazan'. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensation without a license are prohibited. |
| Japan | Controlled substance | Designated as a controlled substance effective March 25, 2015. |
| Sweden | Illegal | Classified as an illegal substance since January 2016. |
| Switzerland | Controlled (Verzeichnis E) | Specifically named and controlled under Verzeichnis E of Swiss narcotics legislation. |
| United Kingdom | Illegal (Psychoactive Substances Act) | Production, supply, and import prohibited under the Psychoactive Substances Act 2016, which came into effect on May 26, 2016. |
| United States | Unscheduled | Not directly scheduled under the Controlled Substances Act. However, due to structural similarities with mescaline, sale for human consumption or use for illicit purposes could potentially be prosecuted under the Federal Analogue Act. |